Hepion Pharmaceuticals Inc expected to post a loss of $2.63 a share - Earnings Preview

Hepion Pharmaceuticals

05/04/2024 21:16

* Hepion Pharmaceuticals Inc  HEPA.OQ   HEPA.O  is expected
to report results on April 8 (estimated) for the period ending
December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Hepion Pharmaceuticals
Inc is
for a loss of $2.63 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Hepion
Pharmaceuticals Inc is $26.00​, above​ its last closing price
of $2.64. ​​​

This summary was machine generated April 5 at 20:16 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)